TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

Sanofi's Multiple Sclerosis Drug Faces Trial And Regulatory Setbacks

Benzinga Logo Benzinga • •By Vandana Singh
Sanofi's Multiple Sclerosis Drug Faces Trial And Regulatory Setbacks

Sanofi announced its multiple sclerosis drug tolebrutinib failed to meet primary endpoint in a phase 3 trial for primary progressive multiple sclerosis, leading the company to halt regulatory registration efforts for this indication.

Insights
SNY   negative

Failed phase 3 trial for tolebrutinib in primary progressive multiple sclerosis, will not pursue regulatory registration, stock price dropped 1.77% in premarket trading